RoslinCT Appoints Professor Sir Peter Mathieson and Alexander Vos as New Non-Executive Directors

RoslinCT, a leading cell and gene therapy Contract Development and Manufacturing Organisation (CDMO), is pleased to announce the appointment of Professor Sir Peter Mathieson MB BS (Hons), PhD, FRCP, FRCPE, FMedSci, FRSE, FRSA and Alexander Vos as new Non-Executive Directors.

Want to read more?

Subscribe to ncrjournal.com to keep reading this exclusive post.

Subscribe Now